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Abstract
Introduction: In this pre-clinical in vitro study conducted in estrogen receptor positive (ER+) breast cancer cells,
we have characterized the effects of insulin-like growth factor I (IGF-1) on the cytostatic and cytotoxic action of
antiestrogen treatment when used as a single agent or in combination with the antiprogestin mifepristone (MIF).
Our goal was to identify new molecular targets to improve the efficacy of hormonal therapy in breast cancer
patients that have a poor response to hormonal therapy, in part, due to high circulating levels of unbound
insulinIGF-1.
Methods: IGF-1-mediated effects on cytostasis and apoptotic cell death were determined with cell counts
conducted in the presence and absence of trypan blue; enzyme-linked immunosorbent assays to determine the
intracellular levels of cleaved cytokeratin 18, a marker of epithelial cancer cell apoptosis; and immunoblot analysis
to determine the levels of cleaved poly-ADP ribose polymerase (PARP) and lamin A that result from caspase-
dependent apoptosis. Cytotoxicity was further characterized by determination of the levels of reactive oxygen
species (ROS) and the percent of mitochondrial membrane depolarization in cell populations treated with the
different hormones in the presence and absence of IGF-1. Small molecule inhibitors of the dual-specificity protein
kinase MEK1, MEK1 siRNA, Bim siRNA, and vectors overexpressing MEK1 wild type and mutant, dominant negative
cDNA were used to identify key IGF-1 downstream prosurvival effectors.
Results: IGF-1, at physiologically relevant levels, blocked the cytotoxic action(s) of the antiestrogens 4-
hydroxytamoxifen (4-OHT) and tamoxifen (TAM) when used as single agents or in combination with the
antiprogestin MIF. The antiapoptotic action of IGF-1 was mediated primarily through the action of MEK1. MEK1
expression reduced the levels of ROS and mitochondrial membrane depolarization induced by the hormonal
treatments via a mechanism that involved the phosphorylation and proteasomal turnover of the proapoptotic BH3-
only Bcl-2 family member Bim. Importantly, small-molecule inhibitors of MEK1 circumvented the prosurvival action
of IGF-1 by restoring Bim to levels that more effectively mediated apoptosis in ER+ breast cancer cells.
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Conclusion: his study provides strong support for the use of MEK1 inhibitors in combination with hormonal
therapy to effectively affect cytostasis and activate a Bim-dependent apoptotic pathway in ER+ breast cancer cells.
We discuss that MEK1 blockade may be a particularly effective treatment for women with high circulating levels of
IGF-1, which have been correlated to a poor prognosis.
Introduction
Breast cancer is a leading cause of cancer among
women in the United States and approximately 60% to
70% of these breast cancers express estrogen receptor
alpha (ERa) [1-3]. Estrogen binding to ERa induces
both genomic and nongenomic actions of the ER, which
ultimately lead to increased breast cancer cell growth.
Over the past three decades, the selective estrogen-
receptor modifier tamoxifen (TAM) has been used as an
effective agent in adjuvant therapy and for the preopera-
tive treatment for ER+ breast cancer. TAM acts as a
competitive inhibitor and prevents estrogen binding to
the ER, blocking the proliferative and prosurvival effects
of estrogen. However, only about two thirds of all ER+
breast tumors are initially responsive to TAM therapy
[4]. Moreover, the development of resistance to TAM
and other antiestrogens occurs often in breast cancer
patients and is a major clinical concern [3,5]. To under-
stand the mechanisms of intrinsic and acquired resis-
tance to antiestrogens, numerous in vitro studies have
been conducted, and the multiple mechanisms described
by these studies have been reviewed [5,6]. However, it is
still not clear which mechanisms commonly contribute
to antiestrogen resistance in patients. Even with antihor-
monal therapies that severely deplete the estrogenic
environment of the breast cancer cells, such as aroma-
tase inhibitors, both inherent and acquired resistance
occurs [7]. The fact that antiestrogen resistance is still a
major obstacle to successful antiestrogen therapy under-
scores the importance of investigating new therapies or
identifying effective combination therapies for the treat-
ment of ER+ breast cancer.
Because progesterone binding to the progesterone
receptors (PRs), like estrogen binding to ERs, is growth
stimulatory for breast cancer cells, using antagonists to
both receptors to block tumor growth may be an attrac-
tive treatment option for ER+ and PR+ breast cancers.
Such a combination therapy may be particularly applic-
able for breast cancer patients with PR A-rich tumors
that typically show a poor disease-free survival rate [8].
MIF, also referred to as RU486, is the most commonly
used antiprogestin. MIF effectively antagonizes the activ-
ities of the PR and has served as a prototype antiproges-
tin to block PR function in various breast cancer cell
models used in preclinical in vitro studies [reviewed in
[9]]. Recent studies using in vivo models have further
established a growth-stimulatory role for progestins and
an important antitumor role for MIF and other antipro-
gestins [10,11]. Further, a recent study on breast cell
proliferation in premenopausal women provided evi-
dence for a protective effect of MIF monotherapy on
the breast epithelium through its ability to block breast
epithelial cell proliferation [12].
In vitro studies conducted in ER+ breast cancer cell
models by our laboratory [11,13,14] and others [15,16]
showed that the combination of an antiestrogen plus an
antiprogestin induced significantly higher levels of cytos-
tasis and cytotoxicity (cell death) than did treatment
with the antiestrogen or antiprogestin used as a single
agent. Our previous studies also showed superior effi-
cacy of this combined treatment against antiestrogen-
resistant, ER+ PR+ breast cancer cells in comparison to
antiestrogen treatment [17]. Further, our studies pro-
vided strong evidence that the antiproliferative effects of
MIF are mediated primarily via its binding to the PR
and not via binding to the glucocorticoid and mineralo-
corticoid receptors [13].
In preclinical studies, MCF-7 cells, which express both
ER and PR, have often served as the prototype ER+ breast
cancer model system. MCF-7 cells show E2-dependent
growth and are growth stimulated by progestin binding
to the PR [11,14,17]. In addition, IGF-1 stimulates the
proliferation of MCF-7 cells, and cross-talk between ER
and IGF-1R is required to stimulate maximal growth of
MCF-7 cells [18]. IGF-1 binding to IGF-1R activates its
tyrosine kinase activity and downstream signaling cas-
cades [19], which include the phosphorylation and activa-
tion of MEK1/MAPK1/2 and PI3K/AKT signaling [20].
Activation of MAPK1/2, also referred to as extracellular
signal-regulated-kinases ERK1 (p44) and ERK2 (p42), and
AKT can ultimately increase breast cancer cell prolifera-
tion [21] and survival [22,23]. AKT-mediated signaling is
viewed as a determinant in a breast cancer response to
antiestrogen treatment [24]. A key role for AKT signaling
in endocrine response is supported by the recent clinical
study in which the targeting of mTOR, a downstream
effector of AKT, sensitized ER+ breast cancers to aroma-
tase inhibitors [25]. MEK1/MAPK signaling also regu-
lates cell growth and/or differentiation, but is not
typically thought of as a key antiestrogen resistance
mechanism or as a key effector of cell survival in breast
cancer cells undergoing hormonal therapy [26]. However,
MEK1 activation and subsequent phosphorylation of the
MAPKs is associated with a poor response to
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antihormonal therapy and decreased patient survival in
clinical breast cancer [27,28], and a recent study deter-
mined that blockade of MAPK affects co-repressor
recruitment and potentiates 4-OHT action [29].
In this study, we demonstrate a critical prosurvival role
for the IGF-1/MEK1signaling axis in breast cancer cells
undergoing antiestrogen and antiprogestin treatment and
uniquely demonstrate that the underlying mechanism of
MEK1-mediated survival is via blockade of the proapop-
totic action of the BH3-only protein BimEL.
Materials and methods
Cell culture
MCF-7 and T-47D ER+ breast adenocarcinoma cells
(early passage) were procured from the American Type
Culture Collection (Rockville, MD, USA) and cultured, as
previously described [17,30]. Before hormonal treat-
ments, cells were placed in DMEM-F12 medium (Invitro-
gen, Carlsbad, CA, USA), supplemented with 5% dextran-
coated charcoal stripped fetal bovine serum (DCC FBS;
Hyclone, Logan UT, USA), 2% antibiotics-antimycotics
(Invitrogen), 1% sodium pyruvate (Invitrogen) and 10 μg/
ml insulin (Sigma-Aldrich, St Louis, MO, USA). For hor-
monal treatments, cells were seeded either in the absence
or presence of insulin, allowed to adhere to the culture
vessel for 16 to 24 hours, and then treated with one of
the following: 10 nM estradiol (E2; Sigma), 10 nM E2
plus 1 μM 4-OHT in the presence or absence of 10 μM
MIF (Sigma Aldrich). For experiments in which cells
were seeded in medium containing insulin, cells were
washed with HBSS to remove insulin, before administra-
tion of hormonal treatment. As indicated in the text and
figure legends, hormonal treatments also were conducted
in the presence of the following agents alone or in combi-
nation: 10 μ;g/ml Insulin (Sigma),1-20 ng/ml IGF-1
(Novozymes/Gropep, North Rocks, NSW, Australia), 5
μM U0126 (EMD Biosciences, Billerica, MA, USA), 25 or
50 μ;M PD 98059 (Calbiochem), and/or 500 μ;M vitamin
E (Sigma Aldrich).
Cell counts and clonogenic assay
Cells were evenly seeded in triplicate at a density to
attain 50% to 70% confluence within 24 hours and trea-
ted with drugs and/or hormones, as described in the fig-
ure legends. For cell counts of the detached cell
population, detached cells were collected, concentrated
by centrifugation, and counted by using a hemacyt-
ometer. Adherent cells were washed twice with cold 1×
PBS, trypsinized, diluted in Isoton II, and counted by
using a Coulter Counter. For total cell counts, the
adherent, monolayer cells were released from the culture
dish by trypsinization and pooled with the detached cells
collected from the medium. Before all cell counts, the
cells were syringed 3 times with a 25 7/8-gauge needle
to obtain single-cell suspension. Where indicated in the
figure legends, trypan blue (0.08%; Sigma Aldrich) was
added to the cell suspension for the identification of
dead cells; trypan blue-positive cells demonstrate com-
promised plasma membrane integrity in dying or dead
cells. Cell counts are graphed as the mean ± SD values,
and statistically significant differences between treat-
ment groups are described in the figure legends.
Mitochondrial membrane depolarization assay
The mitochondrial depolarization assay was conducted
by using the compound 5,5’,6,6- tetrachloro-1,1’,3,3’-tet-
raethyl-benzimidazolylcarbocyanine, also referred to as
JC-1, according to the manufacturer’s protocol (Biotium,
Inc., Hayward, CA, USA) and as previously described by
our laboratory [31]. All experiments were performed in
triplicate. The results are expressed as the mean ± SD
values, and statistically significant differences between
treatment groups are described in the figure legends.
Protein harvest, immunoblotting, and l-phosphatase
treatment
Cell lysates were harvested as described in our previous
studies [13,17,30,31]. Immunoblotting was conducted
according to the manufacturer’s protocol by using pri-
mary antibodies to: LC3 (ab48394), p62 (ab56416),
cleaved lamin A (ab52300) [Abcam]; cleaved PARP
(9541), phospho-p44/42 MAP kinase (Thr202/Tyr204,
9106), total MAPK (9102), Akt (9272), phospho-Akt
(Ser473, 9271), MEK1 (9124), pBim (4581), and Bim
(2819) [Cell Signaling]; pERK1/2 (SC-7383), ERa (SC-
8002), and IGF-1Rb (SC-713) [Santa Cruz Biotechnol-
ogy]; and b-actin (A5441) [Sigma]. Secondary antibodies
included antimouse IgG (715-035-150) and anti-rabbit
IgG (711-035-152) [Jackson ImmunoResearch]. Immu-
nodetection was performed by using the ECL detection
system (34080; Thermo Scientific Pierce) and HyBlot CL
autoradiography film (E3012, Denville Scientific Inc.,
Parsippany, NJ, USA). Densitometry was used to com-
pare signal intensity among samples by using b-actin as
the loading control.
For phosphatase experiments, cell lysates were pre-
pared and analyzed as recently described [32] in a tri-
ton-based lysis buffer with protease inhibitors, but not
NaF or Na3VO4. The lysates (50 μ;g protein) were incu-
bated for 20 minutes or 1 hour with lambda phospha-
tase (l-PPase (15 μ;g/200 U) (NEB; PO753S) or calf
alkaline phosphatase (CIP, 50 U) (NEB, M02909),
according to the manufacturer’s recommendations.
Detection of cleaved cytokeratin 18
Evenly seeded adherent cells were treated with the drugs
and/or hormones for 48, 72, and 96 hours. Detached
and adherent cells were collected and lysed in ice-cold
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lysis buffer (10 mM Tris-HCl, pH 7.4/10 mM MgCl2/
150 mM NaCl/0.5% NP-40), and the cleavage of cyto-
keratin 18 was measured in the cell extracts by using
Peviva M30-Apoptosense ELISA, according to the man-
ufacturer’s protocol (DiaPharma, West Chester, OH,
USA). Three independent experiments were performed
for each treatment group. Values expressed as the mean
± SD and statistically significant differences between
treatment groups are described in the figure legends.
Reactive oxygen species (ROS) determination
MCF-7 cells (5 × 104 cells in 200 μl per well of a 96-
well dish) were seeded. After 24 hours to allow cell
attachment, cells were treated with the drugs and/or
hormones for various times. At the end of the experi-
mental period, the cells were washed with HBSS and
loaded with 25 μM 5(6)-carboxy-2’,7’-dichlorofluorescein
diacetate (CM-H2DCFDA, C6827; Invitrogen) for 30
minutes. This nonfluorescent ester CM-H2DCFDA
enters cells and is deacetylated to nonfluorescent 5-(and
-6)-chloromethyl- 2’,7’-dichlorodihydrofluorescein (CM-
H2DCF) by cellular esterases. ROS rapidly oxidizes CM-
H2DCF to the highly fluorescent 5- (and 6-) chloro-
methyl-2’,7’-DCF (CM-DCF). After 30 minutes of incu-
bation, intracellular ROS levels are directly proportional
to CM-DCF generation. To quantify the level of intra-
cellular CM-DCF, the cells were washed with HBSS to
remove extracellular CM-DCF, treatment medium was
replaced, and cells were incubated at 37°C for a short
recovery period (0 to 5 minutes). CM-DCF fluorescence
was measured at an excitation wavelength of 485 nm
and emission at 520 nm on a fluorescent plate reader
(Tecan Spectraflour Plus). Values are expressed as mean
± SD of three independent experiments, and statistically
significant differences between treatment groups are
described in the figure legends.
Downregulation of MEK1 or Bim with RNA interference
RNA interference (RNAi) targeted to MEK1 or Bim (M-
003571-00 and M004383-02-0020, respectively, Dharma-
con) was carried out according to the manufacturer’s
protocol. Cells were seeded in DMEM-F12 medium con-
taining 5% DCC FBS (antibiotic free). Twenty-four
hours after seeding, cells were washed and treated with
either MEK- or Bim-targeting RNAi by using Oligofec-
tamine (Invitrogen; 12252-011). For controls, cells were
treated with scrambled RNAi. Twenty-four or forty-
eight hours after RNAi treatment, the cells were treated
with drugs and/or hormones for various times, and har-
vested for either protein analysis or cell counts.
Overexpression of MEK1 cDNAs
A MEK1-GFP plasmid expression vector [33] was pur-
chased from Addgene (Plasmid 147461; Billerica, MA,
USA), and the pEGFP-N1 parent vector, from Clone-
tech, 6085-1. Twenty-four hours before transfection,
MCF-7 cells were seeded in DMEM-F12 medium con-
taining 5% DCC FBS (antibiotic free) to yield approxi-
mately 50% confluence. Cells were then transfected with
plasmids (4.0 μg) by using lipofectamine LTX (Invitro-
gen) according to the manufacturer’s protocol. The
transfected cell population was maintained in culture
medium for 24 hours, treated with drugs for various
times, and harvested for either ROS determinations,
mitochondrial membrane permeabilization, or protein
analysis.
Infections with recombinant adenovirus expressing MEK1
Recombinant adenovirus [34] expressing dominant-
negative MEK1 (Ad-CMV-MEK1DN, Cat 1165; Vector
Biolabs) or the Ad-CMV-Null control vector (Ad-CMV,
Cat 1300; Vector Biolabs) [35] was used to infect cells at
an estimated multiplicity of infection of 100, which
results in > 80% infection of ER+ breast cancer cells.
Twenty-four hours after infection, cells were treated
with hormones and/or drugs for various times, and har-
vested for either ROS determinations, mitochondrial
membrane permeabilization, or protein analysis.
Statistical analyses
For all experiments in which data are graphed as the
mean ± SD values, a minimum of three independent
experiments was performed. Comparisons were made
between treatment groups, and statistically significant
differences were determined by one-way ANOVA by
using Sigma Plot 11 for Windows, as identified in the
figure legends.
Results
Physiologic levels of IGF-1 inhibit 4-OHT- and MIF-
induced cell death by reducing the levels of oxidative
stress in MCF-7 breast cancer cells
In past studies, we reported that 4-OHT and/or MIF
treatment induces MCF-7 cell detachment from the
monolayer and demonstrated that the detached cells
were undergoing caspase-dependent apoptosis with clea-
vage of PARP, lamin A, and high-molecular-weight
DNA as measurable apoptotic markers [13,14,17]. These
past studies were conducted in phenol red-free DMEM/
F12 medium supplemented with 5% FBS that was
depleted of endogenous steroid hormones through char-
coal stripping. However, we now show that if hormonal
treatments are conducted in this medium plus 10 μ;g/ml
insulin, as recommended by the ATCC for optimal
growth of MCF-7 cells, cell detachment and cell death
are not detected (see Additional file 1). This concentra-
tion of insulin is supraphysiologic, and insulin at high
doses can bind to and activate the IGF-1R [36]. Thus,
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we hypothesized that the prosurvival effects of insulin
were mediated through the IGF-1R and predicted that
IGF-1, at physiologic doses, would similarly attenuate
the cytotoxic action of 4-OHT and/or MIF. To test this
prediction, experiments were conducted in varying con-
centrations of IGF-1, used in combination with the hor-
monal treatments. These studies showed that IGF-1 at
10 and 20 ng/ml also attenuated 4-OHT- and/or MIF-
induced cell death, as evidenced by a reduction in the
number of detached, dying cells, while enhancing E2-
mediated cell growth by approximately 50% (Figure 1a).
However, cell counts did show that 4-OHT, MIF, and 4-
OHT plus MIF treatments conducted in the presence of
IGF-1 effectively reduced overall cell number, with the
combination of 4-OHT plus MIF most effectively inhi-
biting cell proliferation (Figure 1a). Western blot analy-
sis further showed predominantly the
hypophosphorylated form of Rb110 in the cells treated
with 4-OHT plus MIF in IGF-1-supplemented medium,
in contrast to significantly higher levels of the hyperpho-
sphorylated, inactive Rb110 present in the cells treated
with either 4-OHT or MIF (Figure 1b; compare lane 8
with lanes 5 to 7). Active, dephosphorylated Rb is
known to play a key role in 4-OHT- and/or MIF-
induced growth arrest of ER+ breast cancer cells in the
G1 phase of the cell cycle [13,17]. So, in the presence of
IGF-1, the combined treatment of 4-OHT plus MIF was
able to induce cytostasis effectively, but did not appear
to affect a significant death response.
Once we established that 20 ng/ml IGF-1 maximally
induced cell proliferation, while blocking cell detachment
(Figure 1 and data not shown), this concentration was
used in all subsequent experiments, including the experi-
ments shown in Figure 1 (b through d), in which we
further characterized the IGF-1 prosurvival action. Speci-
fically, IGF-1-treated cells showed very low levels of
cleaved PARP and lamin A (Figure 1b). Further IGF-1
blocked the ability of 4-OHT and/or MIF treatment to
affect the cleavage of cytokeratin 18 (Figure 1c) and
depolarize the mitochondrial membrane (Figure 1d).
Cytokeratin 18 cleavage, in particular, occurs during cas-
pase-dependent apoptosis in epithelial cells and tumors
derived from epithelial cells [37]. Thus, IGF-1, at physio-
logically relevant concentrations, blocks 4-OHT-induced
and/or MIF- induced apoptotic cell death, which has
been partially characterized in our previous studies and
involves the activation of caspase-9, -8, and -6 [17,30].
Because oxidative stress can be an upstream effector
of caspase activation [38], and is suppressed by IGF-1 in
breast cancer cells [39], we further determined the levels
of ROS in cells undergoing the hormonal treatments in
medium supplemented with or devoid of IGF-1. ROS
levels were determined at various times after treatment
and in multiple independent experiments. These
experiments showed that ROS levels were significantly
higher in cells treated with 4-OHT and/or MIF com-
pared with E2-treated cells, but significantly reduced if
IGF-1 was in the treatment medium. Figure 2a shows
representative levels of ROS in cells treated with hor-
mones for 24 hours in the presence and absence of IGF-
1. The determination of ROS levels in cells harvested at
earlier time points (that is, 1 hour) showed that 4-OHT
plus MIF treatment induced higher levels of ROS than
did either 4-OHT or MIF used as a single agent (data
not shown). An essential role of ROS in mediating cell
death was demonstrated by using the antioxidant vita-
min E. When vitamin E was added to the treatment
medium, no significant increase in ROS levels was noted
in cells treated with 4-OHT and/or MIF at any time
point analyzed (Figure 2b and data not shown). Further,
mitochondrial membrane permeability (Figure 2c) and
the cleavage of PARP and lamin A were minimally
affected (Figure 2d) by hormonal therapy conducted in
the presence of vitamin E. Thus, the proapoptotic
actions of both 4-OHT and MIF require ROS, and the
IGF-1-mediated antiapoptotic action involves a mechan-
ism that, in large part, reduces ROS in hormonally trea-
ted breast cancer cells.
Blockade of MEK1 activity with small-molecule inhibitors
abrogates the antiapoptotic effects of IGF-1 in
hormonally treated ER+ MCF-7 breast cancer cells
MEK1 signaling has been shown to protect against
breast cancer cell death more effectively than PI3K/Akt
signaling under certain cell contexts (that is, nutrient
deprivation) [40]. Thus, we sought to determine whether
MEK1 was a key downstream effector of the IGF-1/IGF-
1R prosurvival signaling that protected MCF-7 cells
from 4-OHT and/or MIF-induced death. Our read-out
of MEK1 activity was the phosphorylation/activation of
the mitogen-activated protein kinases MAPK1/2 that are
activated by MEK1-mediated phosphorylation [41].
Under our treatment conditions and at multiple time
points analyzed, cells treated with IGF-1 and E2 showed
higher levels of MAPK1/2 phosphorylation (designated
pMAPK) than did E2-treated or IGF-1-treated cells
(Figure 3a, b; compare lane 5 with lane 1, and data not
shown). Further, 4-OHT or MIF used as a single agent
or in combination did lead to a significant reduction in
pMAPK1/2 phosphorylation in these cells (Figure 3a).
Nonetheless, at multiple time points analyzed,
pMAPK1/2 in the 4-OHT- and/or MIF-treated cells was
detectable by Western blot (Figure 3b, compare lanes 6
to 8 with lane 5 and data not shown), indicating that
MEK1 action is only moderately suppressed by these
hormonal treatments. Even when treatments were con-
ducted in the absence of IGF-1, active, phosphorylated
MAPK1/2 was detected in 4-OHT- and/or MIF-treated
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cells at multiple time points, including 6 hours (Figure
3b, compare lanes 2 to 4 with lane 1). Thus, MEK1
appears to be active in a large percentage of cells under-
going 4-OHT and/or MIF treatments.
To determine whether the apparent MEK1 activity
imparted a growth or survival advantage to 4-OHT- and/
or MIF- treated cells, we combined the small-molecule
MEK1 inhibitors PD 98059 [42] or U0126 [43] with the
hormonal treatments. In initial experiments, we deter-
mined that PD 98059 and U0126 effectively blocked IGF-
1-and E2-induced MEK1 activity, as evidenced by the lack
of detectable MAPK1/2 phosphorylation, with minimal
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affect on Akt phosphorylation (Figure 3b; compare lanes 9
to 12 with lanes 5 to 9 and data not shown). Importantly,
PD 98059 treatment restored the basal and induced level
of cell detachment (Figure 3c) and cleavage of PARP in
the (Figure 3d) cell populations undergoing 4-OHT and/
or MIF treatment, in addition to reducing cell proliferation
in all treatment groups (Figure 3c). In a similar fashion,
treatment with U0126 also blocked the proliferative (data
not shown) and prosurvival effects of IGF-1 and restored
the cytotoxic action of 4-OHT and MIF, which included
enhancing ROS levels and increasing the percentage of
mitochondrial membrane depolarization (see Additional
files 2a and 2b). Treatment with vitamin E again reduced
the levels of ROS, mitochondrial membrane depolariza-
tion, and cleavage of PARP and lamin A resulting from
MEK1 blockade (see Additional files 2c through 2e). Con-
sidered together, these data show that small-molecule
inhibitors of MEK1 effectively block the proliferative and
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antiapoptotic action of IGF-1 and enhance the ability of 4-
OHT and MIF to induce an ROS-dependent apoptosis in
ER+ MCF-7 breast cancer cells.
Blockade of MEK1 effectively induces death of MCF-7
cells with reduced IGF-1R levels
Both high levels of IGF-1R, as seen in MCF-7 cells, and
low levels of IGF-1R are associated with a higher risk
and a less-favorable clinical prognosis [44]. Thus, we
wanted to determine whether IGF-1 showed similar,
MEK1-dependent prosurvival effects under conditions of
low-level IGF-1R expression. We analyzed a subclone of
MCF-7, designated SX13, that expresses low-level IGF-
1R. SX13 cells harbor the stable integration of an
expression vector containing antisense to IGF-1R,
whereas the parent MCF-7 cells (designated NEO) har-
bor the expression vector lacking the antisense [19].
IGF-1R levels in SX13 and NEO cells differ by at least
twofold (Figure 4a). However, the reduction in IGF-1R
does not sensitize cells to 4-OHT- and/or MIF-induced
cell death. The levels of PARP cleavage in SX13 and
NEO cells in response to 4-OHT and/or MIF treatment
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were similar (Figure 4a). Although SX13 cells were not
growth-stimulated by IGF-1 above E2-stimulated
growth, even under conditions of limiting serum con-
centration (Figure 4b) [19], IGF-1 did block the growth-
inhibitory effects of 4-OHT on SX13 cells. Importantly,
MEK1 blockade restored 4-OHT sensitivity in IGF-1-
supplemented medium (Figure 4c). Further, IGF-1
reduced the cytotoxic action of the 4-OHT-plus-MIF
combination treatment, with detectable reductions in
the numbers of dead cells (trypan blue cells) (Figure
4d). When PD 98059 inhibitor was used to block MEK1
action, however, a significant increase in the numbers of
trypan blue cells was seen in all the treatment groups
(Figure 4d). Microscopic evaluation of SX13 and the
NEO cells after 4-OHT and/or MIF treatment, in the
presence and absence of IGF-1, clearly showed that PD
98059 treatment resulted in a robust reduction in cell
number (data not shown, and Figure 4e, compare c and
d with a and b, respectively). These studies establish
that blockade of MEK1 with small-molecule inhibitors
can circumvent the protective effects of IGF-1 and
increase the cytotoxic, proapoptotic action of 4-OHT
and/or MIF on ER+ breast cancer cells with low and
high levels of IGF-1R.
MEK1 function is required to reduce ROS, which is a
prerequisite of antiestrogen- and/or antiprogestin-
induced cell death
To confirm the role of MEK1 in regulating hormonally
induced ROS and apoptosis, we used RNAi to downre-
gulate MEK1 mRNA, a dominant negative, mutant
MEK1 cDNA to block the action of MEK1, and a wild-
type MEK1 cDNA to force MEK1 overexpression. In
these experiments, targeting MEK1 expression with
siRNA effectively reduced MEK1 protein levels in all
treatment groups (Figure 5a, compare lanes 4 to 6 with
1 to 3). This reduction in MEK 1 expression signifi-
cantly increased both the ROS levels (Figure 5b) and
mitochondrial membrane depolarization (Figure 5c) in
cells subjected to 4-OHT and/or MIF treatment in IGF-
1-supplemented medium. Similar results were obtained
when MEK1 action in MCF-7 cells was blocked by over-
expression of a mutant, MEKDN (see Additional files 3a
to 3c). In stark contrast, the overexpression of MEK1
wild-type cDNA, which led to detectable increases in
MEK1 protein in the transfected cells (Figure 5d),
reduced both the levels of ROS and mitochondrial
membrane depolarization in cells undergoing 4-OHT
and/or MIF treatment (Figure 5e and 5f, respectively).
Thus, MEK1 overexpression in 4-OHT- and/or MIF-
treated cells mimicked the prosurvival effects of IGF-1.
Further, these MEK1 expression studies were consistent
with the results obtained with the small-molecule inhibi-
tors of MEK1 and confirmed a key antiapoptotic role of
a MEK1-dependent pathway in MCF-7 breast cancer
cells undergoing 4-OHT and/or MIF treatments.
MEK1 blockade in antiestrogen and antiprogestin breast
cancer cells induces ROS and cell death via a Bim-
dependent mechanism
The proapoptotic protein Bim/BOD, a member of the
BH3-only group of Bcl-2 family members, is an effector
of cell death on growth-factor withdrawal in many cell
types, including epithelial cells [45]. Further, MEK1/
MAPK1/2 signaling regulates BimEL expression via
phosphorylation that facilitates BimEL degradation by
the proteasome [46]. Thus, we considered Bim to be a
strong candidate for the death effector mediating the
cytotoxicity in hormonally treated MCF-7 cells with
compromised MEK1 activity. Bim has three isoforms
because of alternative splicing: BimEL, BimL, and BimS
[47], with BimEL being the most abundant form
expressed in MCF-7 cells under our treatment condi-
tions (Figure 6a, top panel). BimS, which is the most
cytotoxic Bim isoform and transiently expressed during
apoptosis in other cell types [48], was the most difficult
to detect. The BimL isoform was seen at higher levels in
cells treated with MIF in comparison with E2- or 4-
OHT-treated cells (Figure 6a, top panel: compare lanes
3 and 4 with 1 and lanes 7 to 8 with 5). MIF, but not 4-
OHT, appeared to be inducing BimL.
Close inspection of a lighter exposure of the BimEL
signal (Figure 6a, middle panel) identified a doublet
band, with the upper band being the predominant form
in cells treated with E2 plus IGF-1 (Figure 6a, lane 5).
The lower BimEL band, which is a faster-migrating
BimEL protein, was consistently detected at higher levels
in cells treated with U0126 as a single agent or in com-
bination with 4-OHT (Figure 6b; compare lanes 3 and 4
with lanes 1 and 2 and lanes 7 and 8 with lanes 5 and6),
and/or MIF treatment (Figure 6c and data not shown).
In addition, this lower band was often detected at higher
levels than the upper BimEL band in cells treated with
4-OHT and/or MIF for 60 hours or longer in medium
devoid of IGF-1 (data not shown). Overall, the relative
increase in the levels of the lower BimEL band corre-
lated to the timing of 4-OHT- and/or MIF-induced
cytotoxicity in MCF-7 populations. We predicted that
the lower BimEL band was the dephosphorylated form
of BimEL known to be more stably maintained in cells.
To determine whether phosphorylation was regulating
the levels of either BimEL form, we treated cells with
MG132, a commonly used proteasome inhibitor, which
blocks the degradation of ubiquitinated proteins by the
proteasome [49]. In these experiments, the upper BimEL
protein accumulated in cells treated with MG132 plus
E2, 4-OHT, and/or MIF (Figure 6i; compare lanes 5 and
6 with lanes 1 and 2 and data not shown). In contrast,
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in the cell populations treated with PD 98059 or U0126,
the phosphorylation of BimEL was impaired and did not
significantly increase after MG132 treatment (Figure 6i,
compare lanes 7 and 8 with lanes 5 and 6). Further, the
dephosphorylated status of the lower Bim EL band was
established when protein lysates isolated from cells
exposed to the different hormones were subjected to
calf-intestinal-phosphatase (data not shown) or l-phos-
phatase. Figure 6d shows representative results of l-
phosphatase treatments conducted for 20 minutes and 1
hour that resulted in increased levels of the lower
BimEL band (Figure 6d; compare lane 1 with lanes 2
and 3, respectively). The increase in the lower BimEL
band occurred with a concomitant loss of the upper
BimEL band (Figure 6e; compare lane 1 with lanes 2
and 3, respectively) and was similar in size to the BimEL
form generated by treatment of cells with U0126 (Figure
6e; compare lanes 2 through 4). In comparison, the l-
phosphatase treatment of protein isolated from cells
treated with U0126 only modestly increased the levels of
the lower BimEL band (Figure 6e; compare lane 5 with
lane 4). As an internal control, the loss of pMAPK sig-
nal as a result of CIP (data not shown) and l-phospha-
tase treatment was apparent in all experiments (Figure
6e; lanes 2 and 3 compared with lane 1, and lane 5
compared with lane 4). Thus, these experiments identify
the lower BimEL band as the dephosphorylated from of
BimEL.
Because studies of CYP2D6 polymorphisms do not
clearly show that 4-OHT is a key metabolite involved in
the antitumor effects of TAM treatment in patients [50],
we also performed similar experiments with TAM at a
dose of 5.0 μ;m, commonly used for preclinical in vitro
studies [51]. The results of these experiments showed
that IGF-1 also reduced the ability of TAM, used as a
single agent or in combination with MIF, to induce cell
death (Figure 6f, lane 3 compared with lane 7, and data
not shown); targeting MEK1 with inhibitors led to a
robust increase in the levels of dephosphorylated
BimEL, with a concomitant decrease in the levels of
phosphorylated BimEL; and the levels of dephosphory-
lated Bim EL correlated directly to the cytotoxicity of
MEK1 blockade, as evidenced by increased PARP clea-
vage in cells by 72 hours of treatment (Figure 6f; lanes 8
and 9 compared with lanes 6 and 7).
To confirm that Bim played a key role in apoptotic
cell death induced by antiestrogen and antiprogestin
treatments when conducted in the presence and absence
of MEK1 blockade, we used siRNA to downregulate
Bim expression in MCF-7 cells. These experiments were
performed in medium supplemented with or devoid of
IGF1. The siRNA targeting of Bim was very effective in
reducing BimEL protein expression when conducted in
cells growing in medium devoid of IGF-1 (Figure 7a;
compare lanes 4 to 6 with lanes 1 to 3). Bim downregu-
lation under these growth conditions reproducibly atte-
nuated the ability of 4-OHT and/or MIF, in the
presence or absence of U0126, to induce the cleavage of
PARP and lamin A (Figure 7a; compare lanes 4 to 6
with lanes 1 to 3). Bim downregulation also significantly
reduced ROS levels in the cells treated with 4-OHT
and/or MIF (Figure 7b). The ROS levels in cells treated
with 4-OHT, MIF, and/or U1026 were reduced to levels
present in the control E2-treated cells (Figure 7b).
When IGF-1 was in the treatment medium, siRNA tar-
geting also effectively reduced Bim levels in MCF-7 cells
(Figure 7c and data not shown). The reduction in Bim
expression robustly reduced the proapoptotic action of
U0126 in cells of all treatment groups, but most effec-
tively in the E2- and 4-OHT-treated cells (Figure 7d;
compare lane 5 with lane 2). The siRNA data shown in
Figure 7a and 7b are representative of at least three
independent experiments in which cells were treated in
medium devoid of IGF-1 or supplemented with IGF-1,
respectively. These data provide strong evidence that
Bim is a key death effector for 4-OHT- and/or MIF-
induced cell death, as well as the increased cytotoxicity
provided by treatment with MEK1 inhibitors
The inherent expression level of BimEL in ER+ breast
cancer cells correlates with the magnitude of apoptosis
induced by 4-OHT and/or MIF treatments conducted in
the presence or absence of MEK1 blockade
T-47D is an independent breast cancer cell model that
expresses ER and PR and is commonly used for studies
analyzing the effects of antiestrogen blockade of ER func-
tion [17,30,31]. In comparison to MCF-7 cells, T-47D cells
show lower basal levels of BimEL, and this reduced level
of BimEL expression has been correlated to a reduced
level of paclitaxel-induced apoptosis [52]. Thus, we char-
acterized the level and phosphorylation status of BimEL
relative to the induction of cytostasis and cytotoxicity in
T-47D cells by 4-OHT and/or MIF treatment in the pre-
sence and absence of IGF-1 and under conditions of
MEK1 blockade. Cell counts showed that IGF-1 stimulated
T-47D cell growth above proliferation levels seen in the
E2-treated population and that PD 98059 effectively
reduced the IGF-1-mediated proliferation (Figure 8a).
However, no detectable increase was seen in the number
of trypan blue cells within T-47D cell populations as a
result of any of the treatments, even after extended periods
of treatment (that is, 144 hours) (Figure 8b and data not
shown). By 72 hours of treatment, cleavage of PARP could
be detected in T-47D cells treated with 4-OHT plus MIF
plus U0126 (Figure 8c; compare lane 6 with lanes 1 to 5),
concomitant with a reduction in the levels of procaspase
3, indicative of its activation. Cleavage of PARP and lamin
A was detected in cells treated with MIF, 4-OHT plus
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MIF, and 4-OHT plus U0126, but only at later time points
and at modest levels (data not shown). The 4-OHT-trea-
ted T-47D cells never showed evidence of apoptotic cell
death; neither cleavage of PARP nor that of lamin A was
detected in 4-OHT-treated cells, even after 216 hours of
treatment. In comparison with the cytotoxic effect on
MCF-7 cells, T-47D cells appeared essentially resistant to
apoptosis, with absence of cleavage of PARP and lamin A
in T-47D cells treated with 4-OHT and/or MIF in the
absence or presence of U0126 for 48 hours (Figure 8d;
compare lanes 1 to 4 with lanes 5 to 8, respectively). The
reduced ability of T-47D cells to undergo apoptotic cell
death correlated to an approximate twofold lower level of
basal BimEL expression in T-47D cells compared with
MCF-7 cells. This difference can readily be seen in Figure
8d, in which equal loading of lysates shows no detectable
level of Bim EL in T-47D cells compared with readily
detectable Bim EL expression in MCF-7 cells (Figure 8d;
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compare lanes 5 to 8 with lanes 1 to 4). ROS levels in 4-
OHT- and/or MIF-treated T-47D also were less than
those induced in MCF-7 cells (Figure 8e and data not
shown).
Although apoptotic death was minimally induced in T-
47D cells, treatment with U0126 effectively reduced the
levels of pMAPK1/2 in T-47D cells, which were inher-
ently higher than pMAPK1/2 levels in MCF-7 cells
(Figure 8d). Because pMAPK1/2 levels were at least two-
fold higher in T-47D cells than in MCF-7 cells, we per-
formed experiments with MG132 to determine whether
the intrinsic turnover rate of BimEL was higher in T-47D
cells than in MCF-7 cells. MG132 treatment did not
increase the intracellular levels of BimEL in T-47D cells
(Figure 8f; compare lanes 7 and 8 with lanes 3 and 4).
These data show that the basal level of BimEL expression
can vary between ER+ breast cancer cell models by
mechanisms independent of MEK1/MAPK12-mediated
phosphorylation and proteasomal turnover. Thus, MEK1
targeting may be effective only in ER+ breast cancer cells
with high intrinsic levels of BimEL (schematically sum-
marized in Figure 9).
Discussion
In this study, we provide evidence that an improved
treatment approach for ER+ breast cancer could be the
use of antiestrogen and/or antiprogestin therapy in
combination with the targeted blockade of the dual-
specificity MEK1 kinase. Specifically, this study used a
variety of expression vectors, siRNA targeting, and
small-molecule inhibitors of MEK kinase to demonstrate
the following key data: (a) physiologic levels of IGF-1
protect ER+ breast cancer cells from antiestrogen- and
antiprogestin-induced cell death through an MEK1-
dependent mechanism; (b) MEK1 activation blocks ROS
induction and/or accumulation that is required for anti-
estrogen- and antiprogestin-induced apoptotic cell
death; and (c) MEK1 blockade circumvents IGF-1-
mediated protection and induces a Bim-dependent,
ROS-mediated apoptotic cell death in antiestrogen- and/
or antiprogestin-treated breast cancer cells.
Our studies are based on the hypothesis that targeting
PR along with ER should more effectively reduce breast
cancer cell growth than does treatment with an anties-
trogen, because progesterone, like estrogen, is mitogenic
in the breast [53] and drives mammary tumor prolifera-
tion in multiple model systems. Consistent with a mito-
genic role for PR in breast cancer, an in vivo preclinical
study [54,55] recently showed that MIF treatment actu-
ally prevented the development of mammary carcino-
genesis in mice carrying a mutated BRCA1 gene [55].
Thus, targeting the PR with an antiprogestin like MIF
along with antiestrogen therapy should have added ben-
efit for all ER+ breast cancer patients, and particular
benefit for patients with ER+, antiestrogen-unresponsive
tumors. For example, blockade of the PR may be quite
effective for the subpopulation of ER+ breast cancers
identified by Fuqua and colleagues [8] that are PR-A-
rich and show a very poor disease-free survival rate after
antiestrogen therapy. The fact that MIF treatment is
well tolerated and can block breast epithelial cell prolif-
eration in premenopausal women [12] lends further sup-
port for MIF or other antiprogestins currently being
developed [11,54] to be used in combination with anti-
estrogen therapy. To date, only three clinical trials have
been conducted with MIF. In these trials, MIF was used
as a monotherapy [reviewed in [9]], and two of the trials
showed efficacy of MIF monotherapy similar to that of
TAM therapy against metastatic breast cancer.
In support of targeting both ER and PR as a treatment
approach to breast cancer, our past studies demon-
strated that 4-OHT and MIF more effectively induce
growth arrest and cell death than do either 4-OHT or
MIF treatment of ER+PR+, antiestrogen-sensitive [13,14],
and ER+PR+, antiestrogen-resistant breast cancer cells
[17]. Improved efficacy was also seen when the anties-
trogen ICI 182, 780 (faslodex) was combined with MIF
[17]. Previous in vivo studies with human breast cancer
xenografts in nude mice determined that TAM-plus-
MIF combined treatment effected a more-robust antitu-
mor response than did TAM or MIF [11]. This study
Figure 9 A schematic representation of the role of BimEL and
induction of apoptosis in ER+ breast cancer cells. This model is
a summary of data showing that MEK1 blockade, in addition to
hormonal treatment (antiestrogen or antiprogestin treatment) will
activate Bim via dephosphorylation and induce an ROS-dependent
apoptotic cell death in some ER+ breast cancer cells, particularly if
IGF-1-induced IGF-IR signaling is active.
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still continues to support the concept of using TAM-
plus-MIF combination therapy because this combined
treatment induced a robust cytostatic response in ER+
breast cancer cells treated in medium supplemented
with IGF-1, even though the cytotoxic effects of the
combined treatment were markedly attenuated by IGF-
1. Overall, IGF-1 appears to convert hormonally induced
cytotoxicity to a cytostatic outcome. Because cytostasis
is not a terminal state, breast cancer cells treated in the
presence of IGF-1 could potentially escape antiestrogen-
and/or antiprogestin-induced cytostasis via genetic or
epigenetic changes that lead to the development of resis-
tance. Thus, the use of an antiestrogen with an antipro-
gestin may not completely alleviate problems of
resistance, particularly in patients with high circulating
levels of IGF-1 [56].
Combining a MEK1 inhibitor with antiestrogen and/or
antiprogestin treatment very effectively blocked the pro-
liferative and antiapoptotic effects of IGF-1 in MCF-7
cells. Thus, MEK1 appears to be a key to breast cancer
cell survival and proliferation. A critical prosurvival role
of MEK1 in breast cancer cells is supported by elegant
studies from the Eastman laboratory, which demon-
strated a more critical role of MEK1/MAPK signaling in
breast cancer cell survival than that of Akt signaling
[40]. Our study, however, is quite distinct from the
study by the Eastman laboratory, which did not use hor-
monal therapy, or identify the key role of the proapop-
totic BimEL protein in mediating death in response to
MEK1 blockade in hormonally treated breast cancer
cells. In more recent studies, a prosurvival role for
MEK1 in blocking the cytotoxicity of TNF-a against
MCF-7 cells has also been demonstrated [57]. Thus,
recognition of an important role is growing for MEK1-
mediated signaling in breast cancer cell survival.
Not all published studies concur with a key prosurvi-
val role for MEK1 in hormonally treated breast cancer
cells. For example, Dufourny et al. [58] reported that
mitogenic signaling induced by IGF-1 in MCF-7 human
breast cancer cells was independent of the mitogen-acti-
vated protein kinases (MAPK1/2) and that PD 98059
was unable to restore antiestrogen efficacy. In their
study, PI3-K-induced signaling mediated survival. We
believe that one explanation for inconsistencies in the
reported role(s) of MEK1 versus that of AKT is the
potential variation in MCF-7 cell lines between labora-
tories. This variation can result for a number of reasons,
including the length of passage of the MCF-7 cells; (that
is, early versus late passage [59]) and the fact that an
inherent clonal heterogeneity within the MCF-7 cell line
itself [17] can easily result in the selection of cells with
the fastest proliferation rates. The MCF-7 cells used in
this study were cultured from early-passage MCF-7 cells
(ATCC), still maintain inducible MEK/MAPK signaling,
and do not show constitutive PI3K/Akt signaling. How-
ever, a recent study in lung cancer cells demonstrated
that constitutive AKT expression reduced the level of
BimEL expression to such an extent that, even with
MEK1 blockade, apoptosis was not induced [60]. So it
will be important to investigate how constitutive Akt
activation affects the IGF-1/MEK1 prosurvival axis
described in this study.
Of particular importance, this study provides strong
evidence that not merely the levels of BimEL in cells
determine a cytotoxic outcome. More important, it
appears that the conversion of phosphorylated BimEL to
the dephosphorylated form is a key to the BimEL proa-
poptotic action. Nonetheless, the intrinsic level of
BimEL expression is important, as seen by the studies
using the T-47D breast cancer cells. We show that T-
47D cells express lower levels of basal BimEL protein
and do not readily undergo hormonally induced apopto-
tic cell death, even when cells are treated with an MEK1
inhibitor. So, targeting MEK1 may not yield optimal
BimEL-induced apoptosis in all breast cancer patients
undergoing endocrine therapy for ER+, luminal-type
breast cancers. To identify the breast cancer patients
that will benefit from MEK1 targeting, it will be impor-
tant to determine the various mechanisms regulating
BimEL expression and function in T-47D cells and in
other breast cancer cell models that express low levels
of Bim. To this end, our current studies are aimed at
understanding the multiple pathways that modulate
BimEL expression and function in different ER+ breast
cancer cell models. With the knowledge that BimEL can
affect death in ER+ breast cancer cells treated with anti-
estrogens, it is interesting to speculate that the overex-
pression of Bcl2 that has been identified in antiestrogen-
resistant sublines and breast cancers [61] may be
selected, in part, by the cancer cell survival being depen-
dent on blocking the cytotoxic action of BimEL, as Bcl2
binding to BimEL can abrogate the BimEL ability to
induce apoptosis [62].
Although not a main focus of this article, the prosur-
vival effects of vitamin E (a-tocopherol) described in
this study should be noted. Vitamin E effectively blocked
apoptosis induced by 4-OHT and MIF, in the absence
and presence of MEK1 blockade. Vitamin E treatment
specifically reduced ROS in cells undergoing these treat-
ments. A recent study from the Poirot laboratory [63]
similarly showed that vitamin E blocked TAM induced
breast cancer cell death by inhibiting the production of
oxysterols and ROS. It does appear that at least part of
the cytotoxic action of TAM, 4-OHT, and other SERMs
results from their binding to high-affinity microsomal
antiestrogen binding sites (AEBS), which alters choles-
terol metabolism in such a manner that oxysterols and
ROS accumulate in breast cancer cells [63-65]. Whether
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the increased ROS generated due to MEK1 blockade
somehow results from a similar impairment of choles-
terol metabolism remains to be determined. However, it
is clear that vitamin E blocks the ROS induction/accu-
mulation that results from MEK1 blockade during anti-
estrogen and/or antiprogestin treatments and that the
abrogation of ROS blocks breast cancer cell death. From
these data, it is tempting to speculate that breast cancer
patients undergoing antiestrogen therapy may benefit
from a diet low in vitamin E. Minimally, further studies
are needed the better to define the mechanism of action
of vitamin E, its effect on the MEK1/MAPK prosurvival
axis that contributes to the regulation of the Bim proa-
pototic action, and its effect on the efficacy of endocrine
therapy for breast cancer.
In breast cancer tissue from patients, the downregula-
tion of Bim expression has been associated with breast
cancer progression, in conjunction with downregulation
of SIAH1 expression [66]. However, we are unaware of
any studies analyzing Bim expression levels relative to
endocrine efficacy in patients. Interestingly, Butt and col-
leagues [51] recently reported that PUMA levels in a
small cohort of breast cancer patients predict patient out-
come and tamoxifen responsiveness. PUMA, like Bim, is
a BH3-only protein of the Bcl2 family of proteins and an
apoptotic regulator. PUMA downregulation was shown
to mediate an apoptotic response to TAM in human
breast cancer cells, but manipulation of PUMA levels
alone was unable to ameliorate completely TAM-induced
apoptosis [51]. Butt and colleagues proposed that there is
a “complex interplay between numerous apoptotic regu-
lators in coordinating the cytotoxic, endocrine response.”
Our data are in full agreement with this prediction and
support the conclusion that dephosphorylated Bim EL
will be one of the apoptotic regulators important in pre-
dicting endocrine response. An already-known interplay
exists between Bim and Puma proteins in regulating tax-
ane-induced cell death in breast cancer cells. In this
response, PUMA displaces Bim from binding Bcl2, so
Bim is free to affect negatively the mitochondrial integrity
and execute its proapoptotic function [67]. Our study,
combined with these recent studies, allow us to predict
that the regulation of Bim, along with PUMA in breast
cancer cells, will be pivotal to their response to hormonal
therapy and some chemotherapies.
Conclusions
This study has identified the IGF-1/IGF-IR/MEK pro-
survival axis that exists in ER+ breast cancer cells to
attenuate significantly the cytotoxic action of antiestro-
gen and antiprogestin treatment, with little effect on the
antiproliferative action of these hormones. We further
identified BimEL as the death effector being regulated
by the IGF-1/IGF-IR/MEK prosurvival axis. Targeting
MEK1 in conjunction with hormonal therapy as an
initial treatment option would be a new approach and
should be considered, because the recurrence of breast
cancer in women receiving SERMs is still a major clini-
cal challenge, and a large number of ER+ breast cancers
are initially resistant to antiestrogen therapy, possibly
due to IGF-1-mediated survival effects [56].
Additional material
Additional file 1: Insulin protects ER+ breast cancer cells from 4-
OHT and MIF-induced cytotoxicity. MCF-7 cells were treated with
hormones in the presence or absence of insulin (10 mg/ml). At various
times of treatment, representative live images of cells were captured by
using phase-contrast microscopy (a); adherent versus detached cells
were counted (b); or cells were harvested for protein, which was
analyzed with immunoblotting to determine levels of cleaved PARP (c),
which is a marker of apoptosis in MCF-7 cell populations.
Additional file 2: U0126, a selective inhibitor of MEK1, induces ROS-
dependent apoptosis in MCF-7 cells undergoing hormonal
treatments in the presence or absence of IGF-1. (a, b) Cells treated
with hormones in the presence of IGF-1 (20 ng/ml) plus U0126 (5 mM;
30 minutes pretreatment) versus treatments conducted in the absence of
U0126 showed significant increases in ROS levels and mitochondrial
depolarization. (c through e) However, the increased ROS levels,
mitochondrial membrane permeabilization, and increased levels of
cleaved PARP and lamin A (markers of apoptosis) were significantly
reduced if cells were pretreated with vitamin E (500 μ;M, 30-min
pretreatment) under all treatment conditions.
Additional file 3: Overexpression of a MEK1 dominant negative
mutant protein (MEKDN) induces ROS-dependent apoptosis in MCF-
7 cells undergoing hormonal treatments in the presence of IGF-1. In
multiple independent experiments, MCF-7 cells infected with Ad-CMV-
MEK1DN for various time periods showed statistically significant increases
in ROS levels (a, b), and in the percentage of mitochondrial membrane
depolarization in the infected MCF-7 cell populations, as compared with
MCF-7 cells infected with Ad-CMV control vector (c) .
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4-OHT: 4-hydroxytamoxifen; ER: estrogen receptor; IGF-1: insulin-like growth
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cl PARP: cleaved poly-ADP ribose polymerase; PR: progesterone receptor; Rb:
retinoblastoma protein; ROS: reactive oxygen species; TAM: tamoxifen.
Acknowledgements
We thank Dr. Vadivel Ganapathy for critical reading of this manuscript. This
work was supported by NIH grants CA70897 and CA121438 to P.V.S.
Author details
1Department of Cellular Biology and Anatomy, Georgia Health Sciences
University, 1459 Laney Walker Blvd., Augusta, GA 30912, USA. 2Department of
Cancer Biology, Vanderbilt University, 2220 Pierce Ave., Nashville, TN 37232,
USA. 3Division of Endocrinology, Diabetes and Bone Diseases, Mount Sinai
School of Medicine, 1428 Madison Ave, New York, NY 10029, USA. 4Institute
of Vascular Biology, Georgia Health Sciences University, 1459 Laney Walker
Blvd., Augusta, GA 30912, USA. 5Department of Biochemistry, Georgia Health
Sciences University, 1459 Laney Walker Blvd., Augusta, GA 30912, USA.
6Medical College of Georgia Cancer Center, Georgia Health Sciences
University, 1410 Laney Walker Blvd., Augusta, GA 30912, USA.
Periyasamy-Thandavan et al. Breast Cancer Research 2012, 14:R52
http://breast-cancer-research.com/content/14/2/R52
Page 18 of 20
Authors’ contributions
PVS conceived the study. PVS, SPT, DL, MM, SH, and MT participated in the
experimental design, data interpretation, and manuscript preparation. SPT,
ST, MRD, WHJ, AEW, AS, and PVS performed and analyzed cell-proliferation/
death assays, immunoblotting, and RNAi targeting experiments. SPT, ST, MT,
and PVS analyzed data and performed statistical analysis. All authors read
and approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 5 May 2011 Revised: 13 February 2012
Accepted: 19 March 2012 Published: 19 March 2012
References
1. Cutler W, Burki R, Genovesse E, Zacher M: Breast cancer in
postmenopausal women: what is the real risk? Fertil Steril 2009, 92:S16.
2. SEER Cancer Statistics Review, 1975-2007. Edited by: Altekruse SFKC,
Krapcho M, Neyman N, Aminou R, Waldron W, Ruhl J, Howlader N,
Tatalovich Z, Cho H, Mariotto A, Eisner MP, Lewis DR, Cronin K, Chen HS,
Feuer EJ, Stinchcomb DG, Edwards BK. Bethesda, MD: National Cancer
Institute; 2009:.
3. Jordan VC, O’Malley BW: Selective estrogen-receptor modulators and
antihormonal resistance in breast cancer. J Clin Oncol 2007, 25:5815-5824.
4. Herynk MH, Fuqua SA: Estrogen receptors in resistance to hormone
therapy. Adv Exp Med Biol 2007, 608:130-143.
5. Musgrove EA, Sutherland RL: Biological determinants of endocrine
resistance in breast cancer. Nat Rev Cancer 2009, 9:631-643.
6. Schoenlein PV, Periyasamy-Thandavan S, Samaddar JS, Jackson WH,
Barrett JT: Autophagy facilitates the progression of ERalpha-positive
breast cancer cells to antiestrogen resistance. Autophagy 2009, 5:400-403.
7. Chumsri S, Howes T, Bao T, Sabnis G, Brodie A: Aromatase, aromatase
inhibitors, and breast cancer. J Steroid Biochem Mol Biol 2011, 125:13-22.
8. Hopp TA, Weiss HL, Hilsenbeck SG, Cui Y, Allred DC, Horwitz KB, Fuqua SA:
Breast cancer patients with progesterone receptor PR-A-rich tumors have
poorer disease-free survival rates. Clin Cancer Res 2004, 10:2751-2760.
9. Klijn JG, Setyono-Han B, Foekens JA: Progesterone antagonists and
progesterone receptor modulators in the treatment of breast cancer.
Steroids 2000, 65:825-830.
10. Liang Y, Besch-Williford C, Brekken RA, Hyder SM: Progestin-dependent
progression of human breast tumor xenografts: a novel model for
evaluating antitumor therapeutics. Cancer Res 2007, 67:9929-9936.
11. El Etreby MF, Liang Y: Effect of antiprogestins and tamoxifen on growth
inhibition of MCF-7 human breast cancer cells in nude mice. Breast
Cancer Res Treat 1998, 49:109-117.
12. Engman M, Skoog L, Soderqvist G, Gemzell-Danielsson K: The effect of
mifepristone on breast cell proliferation in premenopausal women
evaluated through fine needle aspiration cytology. Hum Reprod 2008,
23:2072-2079.
13. Schoenlein PV, Hou M, Samaddar JS, Gaddy VT, Thangaraju M, Lewis J,
Johnson M, Ganapathy V, Kallab A, Barrett JT: Downregulation of
retinoblastoma protein is involved in the enhanced cytotoxicity of 4-
hydroxytamoxifen plus mifepristone combination therapy versus
antiestrogen monotherapy of human breast cancer. Int J Oncol 2007,
31:643-655.
14. El Etreby MF, Liang Y, Wrenn RW, Schoenlein PV: Additive effect of
mifepristone and tamoxifen on apoptotic pathways in MCF-7 human
breast cancer cells. Breast Cancer Res Treat 1998, 51:149-168.
15. Bardon S, Vignon F, Montcourrier P, Rochefort H: Steroid receptor-
mediated cytotoxicity of an antiestrogen and an antiprogestin in breast
cancer cells. Cancer Res 1987, 47:1441-1448.
16. Thomas M, Monet JD: Combined effects of RU486 and tamoxifen on the
growth and cell cycle phases of the MCF-7 cell line. J Clin Endocrinol
Metab 1992, 75:865-870.
17. Gaddy VT, Barrett JT, Delk JN, Kallab AM, Porter AG, Schoenlein PV:
Mifepristone induces growth arrest, caspase activation, and apoptosis of
estrogen receptor-expressing, antiestrogen-resistant breast cancer cells.
Clin Cancer Res 2004, 10:5215-5225.
18. Santen RJ, Fan P, Zhang Z, Bao Y, Song RX, Yue W: Estrogen signals via an
extra-nuclear pathway involving IGF-1R and EGFR in tamoxifen-sensitive
and -resistant breast cancer cells. Steroids 2009, 74:586-594.
19. Neuenschwander S, Roberts CT Jr, LeRoith D: Growth inhibition of
MCF-7 breast cancer cells by stable expression of an insulin-like
growth factor I receptor antisense ribonucleic acid. Endocrinology 1995,
136:4298-4303.
20. Casa AJ, Dearth RK, Litzenburger BC, Lee AV, Cui X: The type I insulin-like
growth factor receptor pathway: a key player in cancer therapeutic
resistance. Front Biosci 2008, 13:3273-3287.
21. Lobenhofer EK, Huper G, Iglehart JD, Marks JR: Inhibition of mitogen-
activated protein kinase and phosphatidylinositol 3-kinase activity in
MCF-7 cells prevents estrogen-induced mitogenesis. Cell Growth Differ
2000, 11:99-110.
22. Yan Y, Haas JP, Kim M, Sgagias MK, Cowan KH: BRCA1-induced apoptosis
involves inactivation of ERK1/2 activities. J Biol Chem 2002,
277:33422-33430.
23. Datta SR, Brunet A, Greenberg ME: Cellular survival: a play in three Akts.
Genes Dev 1999, 13:2905-2927.
24. Miller TW, Hennessy BT, Gonzalez-Angulo AM, Fox EM, Mills GB, Chen H,
Higham C, Garcia-Echeverria C, Shyr Y, Arteaga CL: Hyperactivation of
phosphatidylinositol-3 kinase promotes escape from hormone
dependence in estrogen receptor-positive human breast cancer. J Clin
Invest 2010, 120:2406-2413.
25. Baselga J, Campone M, Piccart M, Burris HA, Rugo HS, Sahmoud T,
Noguchi S, Gnant M, Pritchard KI, Lebrun F, et al: Everolimus in
postmenopausal hormone-receptor-positive advanced breast cancer. N
Engl J Med 2012, 366:520-529.
26. Atanaskova N, Keshamouni VG, Krueger JS, Schwartz JA, Miller F, Reddy KB:
MAP kinase/estrogen receptor cross-talk enhances estrogen-mediated
signaling and tumor growth but does not confer tamoxifen resistance.
Oncogene 2002, 21:4000-4008.
27. Gee JM, Robertson JF, Ellis IO, Nicholson RI: Phosphorylation of ERK1/2
mitogen-activated protein kinase is associated with poor response to
anti-hormonal therapy and decreased patient survival in clinical breast
cancer. Int J Cancer 2001, 95:247-254.
28. Donovan JC, Milic A, Slingerland JM: Constitutive MEK/MAPK activation
leads to p27(Kip1) deregulation and antiestrogen resistance in human
breast cancer cells. J Biol Chem 2001, 276:40888-40895.
29. Hong W, Chen L, Li J, Yao Z: Inhibition of MAP kinase promotes the
recruitment of corepressor SMRT by tamoxifen-bound estrogen receptor
alpha and potentiates tamoxifen action in MCF-7 cells. Biochem Biophys
Res Commun 2010, 396:299-303.
30. Samaddar JS, Gaddy VT, Duplantier J, Thandavan SP, Shah M, Smith MJ,
Browning D, Rawson J, Smith SB, Barrett JT, Schoenlein PV: A role for
macroautophagy in protection against 4-hydroxytamoxifen-induced cell
death and the development of antiestrogen resistance. Mol Cancer Ther
2008, 7:2977-2987.
31. Periyasamy-Thandavan S, Jackson WH, Samaddar JS, Erickson B, Barrett JR,
Raney L, Gopal E, Ganapathy V, Hill WD, Bhalla KN, Schoenlein PV:
Bortezomib blocks the catabolic process of autophagy via a cathepsin-
dependent mechanism, affects endoplasmic reticulum stress and
induces caspase-dependent cell death in antiestrogen-sensitive and
resistant ER+ breast cancer cells. Autophagy 2010, 6:19-35.
32. O’Reilly LA, Kruse EA, Puthalakath H, Kelly PN, Kaufmann T, Huang DC,
Strasser A: MEK/ERK-mediated phosphorylation of Bim is required to
ensure survival of T and B lymphocytes during mitogenic stimulation. J
Immunol 2009, 183:261-269.
33. Yao Z, Flash I, Raviv Z, Yung Y, Asscher Y, Pleban S, Seger R: Non-regulated
and stimulated mechanisms cooperate in the nuclear accumulation of
MEK1. Oncogene 2001, 20:7588-7596.
34. Walker T, Mitchell C, Park MA, Yacoub A, Rahmani M, Haussinger D,
Reinehr R, Voelkel-Johnson C, Fisher PB, Grant S, Dent P: 17-Allylamino-17-
demethoxygeldanamycin and MEK1/2 inhibitors kill GI tumor cells via
Ca2+-dependent suppression of GRP78/BiP and induction of ceramide
and reactive oxygen species. Mol Cancer Ther 2010, 9:1378-1395.
35. Tian N, Arany I, Waxman DJ, Baliga R: Cytochrome-P450 2B1 gene
silencing attenuates puromycin aminonucleoside-induced cytotoxicity in
glomerular epithelial cells. Kidney Int 2010, 78:182-190.
36. Lee AV, Yee D: Insulin-like growth factors and breast cancer. Biomed
Pharmacother 1995, 49:415-421.
37. Hagg M, Biven K, Ueno T, Rydlander L, Bjorklund P, Wiman KG, Shoshan M,
Linder S: A novel high-through-put assay for screening of pro-apoptotic
drugs. Invest New Drugs 2002, 20:253-259.
Periyasamy-Thandavan et al. Breast Cancer Research 2012, 14:R52
http://breast-cancer-research.com/content/14/2/R52
Page 19 of 20
38. Prasad V, Chandele A, Jagtap JC, Sudheer Kumar P, Shastry P: ROS-
triggered caspase 2 activation and feedback amplification loop in beta-
carotene-induced apoptosis. Free Radic Biol Med 2006, 41:431-442.
39. Oh YI, Kim JH, Kang CW: Oxidative stress in MCF-7 cells is involved in the
effects of retinoic acid-induced activation of protein kinase C-delta on
insulin-like growth factor-I secretion and synthesis. Growth Horm IGF Res
2010, 20:101-109.
40. Ripple MO, Kalmadi S, Eastman A: Inhibition of either phosphatidylinositol
3-kinase/Akt or the mitogen/extracellular-regulated kinase, MEK/ERK,
signaling pathways suppress growth of breast cancer cell lines, but
MEK/ERK signaling is critical for cell survival. Breast Cancer Res Treat 2005,
93:177-188.
41. Whyte J, Bergin O, Bianchi A, McNally S, Martin F: Key signalling nodes in
mammary gland development and cancer: mitogen-activated protein
kinase signalling in experimental models of breast cancer progression
and in mammary gland development. Breast Cancer Res 2009, 11:209.
42. Canagarajah BJ, Khokhlatchev A, Cobb MH, Goldsmith EJ: Activation
mechanism of the MAP kinase ERK2 by dual phosphorylation. Cell 1997,
90:859-869.
43. Davies SP, Reddy H, Caivano M, Cohen P: Specificity and mechanism of
action of some commonly used protein kinase inhibitors. Biochem J
2000, 351:95-105.
44. Papa V, Gliozzo B, Clark GM, McGuire WL, Moore D, Fujita-Yamaguchi Y,
Vigneri R, Goldfine ID, Pezzino V: Insulin-like growth factor-I receptors are
overexpressed and predict a low risk in human breast cancer. Cancer Res
1993, 53:3736-3740.
45. Balmanno K, Cook SJ: Tumour cell survival signalling by the ERK1/2
pathway. Cell Death Differ 2009, 16:368-377.
46. Ley R, Ewings KE, Hadfield K, Howes E, Balmanno K, Cook SJ: Extracellular
signal-regulated kinases 1/2 are serum-stimulated “Bim(EL) kinases” that
bind to the BH3-only protein Bim(EL) causing its phosphorylation and
turnover. J Biol Chem 2004, 279:8837-8847.
47. O’Connor L, Strasser A, O’Reilly LA, Hausmann G, Adams JM, Cory S,
Huang DC: Bim: a novel member of the Bcl-2 family that promotes
apoptosis. EMBO J 1998, 17:384-395.
48. Yamaguchi T, Okada T, Takeuchi K, Tonda T, Ohtaki M, Shinoda S,
Masuzawa T, Ozawa K, Inaba T: Enhancement of thymidine kinase-
mediated killing of malignant glioma by BimS, a BH3-only cell death
activator. Gene Ther 2003, 10:375-385.
49. Lee DH, Goldberg AL: Proteasome inhibitors: valuable new tools for cell
biologists. Trends Cell Biol 1998, 8:397-403.
50. Morrow PK, Serna R, Broglio K, Pusztai L, Nikoloff DM, Hillman GR,
Fontecha M, Li R, Michaud L, Hortobagyi G, Gonzalez-Angulo AM: Effect of
CYP2D6 polymorphisms on breast cancer recurrence. Cancer 2011, doi:
10.1002/cncr.26407.
51. Roberts CG, Millar EK, O’Toole SA, McNeil CM, Lehrbach GM, Pinese M,
Tobelmann P, McCloy RA, Musgrove EA, Sutherland RL, Butt AJ:
Identification of PUMA as an estrogen target gene that mediates the
apoptotic response to tamoxifen in human breast cancer cells and
predicts patient outcome and tamoxifen responsiveness in breast
cancer. Oncogene 2011, 30:3186-3197.
52. Sunters A, Fernandez de Mattos S, Stahl M, Brosens JJ, Zoumpoulidou G,
Saunders CA, Coffer PJ, Medema RH, Coombes RC, Lam EW: FoxO3a
transcriptional regulation of Bim controls apoptosis in paclitaxel-treated
breast cancer cell lines. J Biol Chem 2003, 278:49795-49805.
53. Clarke CL, Sutherland RL: Progestin regulation of cellular proliferation.
Endocr Rev 1990, 11:266-301.
54. Wiehle RD, Christov K, Mehta R: Anti-progestins suppress the growth of
established tumors induced by 7,12-dimethylbenz(a)anthracene:
comparison between RU486 and a new 21-substituted-19-nor-progestin.
Oncol Rep 2007, 18:167-174.
55. Poole AJ, Li Y, Kim Y, Lin SC, Lee WH, Lee EY: Prevention of Brca1-
mediated mammary tumorigenesis in mice by a progesterone
antagonist. Science 2006, 314:1467-1470.
56. Tworoger SS, Rosner BA, Willett WC, Hankinson SE: The combined
influence of multiple sex and growth hormones on risk of
postmenopausal breast cancer: a nested case-control study. Breast
Cancer Res 2011, 13:R99.
57. Sivaprasad U, Basu A: Inhibition of ERK attenuates autophagy and
potentiates tumour necrosis factor-alpha-induced cell death in MCF-7
cells. J Cell Mol Med 2008, 12:1265-1271.
58. Dufourny B, Alblas J, van Teeffelen HA, van Schaik FM, van der Burg B,
Steenbergh PH, Sussenbach JS: Mitogenic signaling of insulin-like growth
factor I in MCF-7 human breast cancer cells requires
phosphatidylinositol 3-kinase and is independent of mitogen-activated
protein kinase. J Biol Chem 1997, 272:31163-31171.
59. Ko Y, Banerji SS, Liu Y, Li W, Liang J, Soule HD, Pauley RJ, Willson JK,
Zborowska E, Brattain MG: Expression of transforming growth factor-beta
receptor type II and tumorigenicity in human breast adenocarcinoma
MCF-7 cells. J Cell Physiol 1998, 176:424-434.
60. Meng J, Fang B, Liao Y, Chresta CM, Smith PD, Roth JA: Apoptosis
induction by MEK inhibition in human lung cancer cells is mediated by
Bim. PLoS One 2010, 5:e13026.
61. Clarke R, Shajahan AN, Riggins RB, Cho Y, Crawford A, Xuan J, Wang Y,
Zwart A, Nehra R, Liu MC: Gene network signaling in hormone
responsiveness modifies apoptosis and autophagy in breast cancer cells.
J Steroid Biochem Mol Biol 2009, 114:8-20.
62. Hubner A, Barrett T, Flavell RA, Davis RJ: Multisite phosphorylation
regulates Bim stability and apoptotic activity. Mol Cell 2008, 30:415-425.
63. Payre B, de Medina P, Boubekeur N, Mhamdi L, Bertrand-Michel J, Terce F,
Fourquaux I, Goudouneche D, Record M, Poirot M, Silvente-Poirot S:
Microsomal antiestrogen-binding site ligands induce growth control and
differentiation of human breast cancer cells through the modulation of
cholesterol metabolism. Mol Cancer Ther 2008, 7:3707-3718.
64. de Medina P, Silvente-Poirot S, Poirot M: Tamoxifen and AEBS ligands
induced apoptosis and autophagy in breast cancer cells through the
stimulation of sterol accumulation. Autophagy 2009, 5:1066-1067.
65. de Medina P, Paillasse MR, Segala G, Khallouki F, Brillouet S, Dalenc F,
Courbon F, Record M, Poirot M, Silvente-Poirot S: Importance of
cholesterol and oxysterols metabolism in the pharmacology of
tamoxifen and other AEBS ligands. Chem Phys Lipids 2011, 164:432-437.
66. Wen YY, Yang ZQ, Song M, Li BL, Yao XH, Chen XL, Zhao J, Lu YY, Zhu JJ,
Wang EH: The expression of SIAH1 is downregulated and associated
with Bim and apoptosis in human breast cancer tissues and cells. Mol
Carcinog 2010, 49:440-449.
67. Kutuk O, Letai A: Displacement of Bim by Bmf and Puma rather than
increase in Bim level mediates paclitaxel-induced apoptosis in breast
cancer cells. Cell Death Differ 2010, 17:1624-1635.
doi:10.1186/bcr3153
Cite this article as: Periyasamy-Thandavan et al.: Insulin-like growth
factor 1 attenuates antiestrogen- and antiprogestin-induced apoptosis
in ER+ breast cancer cells by MEK1 regulation of the BH3-only pro-
apoptotic protein Bim. Breast Cancer Research 2012 14:R52.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Periyasamy-Thandavan et al. Breast Cancer Research 2012, 14:R52
http://breast-cancer-research.com/content/14/2/R52
Page 20 of 20
